OncoGenex Pharmaceuticals (formerly Sonus Pharmaceuticals) is on the hunt for new and better cancer therapies. With its 2008 merger with OncoGenex Technologies, the company took on a new name and an expanded pipeline of investigational oncology drugs. The merger contributed several candidates (including OGX-011, OGX-427, and OGX-225) that fight treatment-resistant tumors. Another candidate, SN2310, is a version of a proven class of oncology drugs called camptothecins. The company previously halted development on another investigational drug, a version of common cancer drug paclitaxel that used the firm's proprietary Tocosol drug delivery technology, following disappointing clinical trial results in 2007.